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Background. Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity in vitro.
Methods. An international, randomized, double-blind, double-dummy, active-controlled trial was conducted to
evaluate the efﬁcacy and safety of COBI versus ritonavir (RTV) as a pharmacoenhancer of atazanavir (ATV) in com-
bination with emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) in treatment-naive patients. The primary
end point was a human immunodeﬁciency virus type 1 (HIV-1) RNA load of <50 copies/mL at week 48 by the
Food and Drug Administration snapshot algorithm; the noninferiority margin was 12%.
Results. A total of 692 patients were randomly assigned to a treatment arm and received study drug (344 in the
COBI group vs 348 in the RTV group). At week 48, virologic success was achieved in 85% of COBI recipients and
87% of RTV recipients (difference, −2.2% [95% conﬁdence interval, −7.4% to 3.0%]); among patients with a base-
line HIV-1 RNA load of >100 000 copies/mL, rates were similar (86% vs 86%). Similar percentages of patients in
both groups had serious adverse events (10% of COBI recipients vs 7% of RTV recipients) and adverse events
leading to discontinuation of treatment with the study drug (7% vs 7%). Median increases in the serum creatinine
level were 0.13 and 0.09 mg/dL, respectively, for COBI and RTV recipients.
Conclusions. COBI was noninferior to RTV in combination with ATV plus FTC/TDF at week 48. Both regi-
mens achieved high rates of virologic success. Safety and tolerability proﬁles of the 2 regimens were comparable.
Once-daily COBI is a safe and effective pharmacoenhancer of the protease inhibitor ATV.
Clinical Trials Registration. NCT01108510.
Keywords. cobicistat; pharmacoenhancer; HIV.
The use of a pharmacoenhancer, primarily low-dose
(100–400 mg/day) ritonavir (RTV), to boost protease
inhibitors (PIs) has had a signiﬁcant impact on the treat-
ment of human immunodeﬁciency virus (HIV) infection
by improving the pharmacokinetic proﬁles of the boosted
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drug, resulting in durable efﬁcacy, high barrier to resistance, and a
reduced pill burden and dosing frequency [1]. Cobicistat (COBI)
is a novel pharmacoenhancer that was developed to boost the
plasma levels of elvitegravir (EVG) or PIs. Preclinical studies dem-
onstrated that COBI is more selective than RTV in inhibiting
CYP3A; has a low potential for induction, which may lead to
fewer or more-predictable drug-drug interactions; and does not
have antiretroviral activity in vitro, which eliminates any potential
of conferring PI resistance when used as a pharmacoenhancer of a
non-PI, such as EVG [2].
In a phase 2 study of treatment-naive patients, COBI was
well tolerated and demonstrated similar efﬁcacy to RTV as a
pharmacoenhancer for atazanavir (ATV) in combination with
emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) [3].
ATV was selected as the PI to be boosted by COBI because it is
the preferred PI for treatment-naive patients [4, 5]. COBI was
also studied as a component of a single-tablet regimen, Stribild
(EVG/COBI/FTC/TDF), in 2 large randomized controlled
trials that demonstrated its efﬁcacy and safety [6, 7].
In this article, we present results of a phase 3 study in treat-
ment-naive patients that compared COBI to RTV as a pharma-
coenhancer for ATV in combination with FTC/TDF.
METHODS
Patients
Study GS-US-216-0114 (clinical trials registration NCT011
08510) is an ongoing phase 3 study assessing the efﬁcacy and
safety of COBI versus RTV in combination with ATV and
FTC/TDF as initial HIV treatment. The study is being conduct-
ed internationally and was approved by institutional review
boards or ethics committees at all investigative centers. All
patients gave written informed consent.
Patients (target enrollment, 700) were HIV type 1 (HIV-1)–
infected adults at least 18 years old with a plasma HIV-1 RNA
level of≥ 5000 copies/mL and no prior use of antiretroviral
agents. An estimated glomerular ﬁltration rate (eGFR) of at least
70 mL/min and sensitivity to ATV, FTC, and TDF by the infect-
ing strain, determined on the basis of HIV-1 genotyping
(GeneSeq assay, Monogram Biosciences, South San Francisco,
CA), were required at screening. Additional inclusion criteria in-
cluded aspartate aminotransferase (AST) and alanine amino-
transferase (ALT) levels of ≤5 times upper limit of normal, a
total bilirubin level of ≤1.5 mg/dL or a normal direct bilirubin
level, an absolute neutrophil count of ≥1000 cells/mm3, a platelet
count of ≥50 000 platelets/mm3, a hemoglobin level of ≥8.5 g/
dL, and a negative result of a serum pregnancy test (if applica-
ble). Positivity for hepatitis B virus surface antigen or hepatitis C
virus antibody was allowed. There was no screening CD4+ T-cell
count requirement; patients with new AIDS-deﬁning conditions
or serious infections within 30 days of screening were excluded.
Randomization and Blinding
Eligible patients were randomly assigned at a 1:1 ratio to receive
either COBI or RTV, each administered once daily. Patients also
received placebo tablets matching the alternative treatment;
thus, investigators, patients, and study staff were blinded to the
treatment group. A computer-generated allocation sequence that
used a block size of 4 was created by Bracket (San Francisco, CA),
and randomization was stratiﬁed by screening HIV-1 RNA level
(≤100 000 copies/mL and >100 000 copies/mL). Investigators
randomly assigned patients to one of the 2 treatment arms by
phone or Internet, using an interactive system (provided and
managed by Bracket).
Procedures
Study visits occurred at weeks 2, 4, 8, 12, 16, 24, 32, 40, and 48.
Patients were to continue blinded treatment assignments with
visits every 12 weeks until week 192. Safety was assessed on the
basis of laboratory test results, physical examination ﬁndings,
and adverse events. Laboratory analyses included hematologic
analysis, serum chemistry analysis, and urinalysis (Covance
Laboratories, Indianapolis, IN) and HIV-1 RNA load (Amplicor
HIV–1 Monitor Test [v1.5]; Roche Diagnostics, Rotkreuz, Swit-
zerland). The HIV-1 genotype (for the genes encoding reverse
transcriptase and protease only) was analyzed at screening,
using the GeneSeq assay. In patients receiving study drugs who
had a conﬁrmed HIV-1 RNA load rebound of ≥400 copies/mL
or did not achieve <400 copies/mL by or after week 8, protease
and reverse transcriptase genotyping and phenotyping assays
were done with PhenoSense GT, PhenoSense Integrase, and
GeneSeq Integrase (Monogram Biosciences). Preliminary
results by treatment group were reviewed by an independent
data monitoring committee (IDMC) when half of the patients
completed week 12 of follow-up and when all patients complet-
ed weeks 24 and 48 of follow-up.
Statistical Analysis
The primary analysis included all clinical, laboratory, and viro-
logic data available after the last patient had completed the
week 48 study visit or prematurely discontinued receipt of the
study drug. The primary end point was the proportion of pa-
tients with virologic suppression (HIV–1 RNA load, <50
copies/mL) at week 48, in accordance with the US Food and
Drug Administration (FDA)–deﬁned snapshot analysis; the in-
tention-to-treat (ITT) population was used to assess the nonin-
feriority of COBI treatment, compared with RTV treatment,
using a conventional 95% conﬁdence interval (CI) approach
with a prespeciﬁed noninferiority margin of 12%. In the FDA
snapshot analysis, patients with an HIV-1 RNA load of <50
copies/mL between days 309 and 378 (the week 48 window)
were classiﬁed as having virologic success. Patients with an
HIV-1 RNA load of≥ 50 copies/mL at the week 48 analysis
window or no HIV-1 RNA data in the week 48 analysis
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window because of missing data or discontinuation of study
drug treatment were considered as not having virologic success.
The baseline HIV-1 RNA load stratum (≤100 000 copies/mL
or >100 000 copies/mL)–weighted difference in the response
rate and its 95% CI were calculated on the basis of a stratum-
adjusted Mantel-Haenszel proportion. For each interim analysis
performed, an α of 0.001 was spent. Therefore, the signiﬁcance
level for the 2-sided test for virologic response at week 48,
according to the FDA snapshot algorithm, for ITT and per-
protocol (PP) populations was 0.048, corresponding to a 95.2%
CI. A sample size of 700 patients provided at least 95% power
to establish noninferiority with respect to the percentage of pa-
tients achieving virologic success at week 48, as deﬁned by the
FDA snapshot analysis, between the 2 treatment groups. This
assumes response rates of 79.5% in both treatment groups [8], a
noninferiority margin of 12%, and a signiﬁcance level of the
test at a 1-sided, 0.025 level. Calculations were made using
nQuery Advisor, version 6.0 (Statistical Solutions, Saugus, MA).
A per-protocol snapshot analysis was conducted that includ-
ed all patients who (1) were randomized into the study, (2) re-
ceived at least 1 dose of study drug, and (3) did not meet any
prespeciﬁed criteria, such as discontinuation of study drug
treatment for reasons other than lack of efﬁcacy with no week
48 HIV-1 RNA load data. Supporting analyses included sub-
group analyses (ie, by age, sex, race, baseline HIV–1 RNA level,
baseline CD4+ T-cell count, and study drug adherence as as-
sessed by pill counts) to assess treatment differences between
speciﬁed subgroups. Additional efﬁcacy end points at week 48
were the achievement and maintenance of an HIV-1 RNA load
of <50 copies/mL, using the FDA-deﬁned time to loss of
virologic response (TLOVR) algorithm [9]; the percentage of
patients with an HIV-1 RNA load of <50 copies/mL, using
missing-equals-failure and missing-equals-excluded methods;
the change from baseline in the HIV-1 RNA load (measured as
log10 copies/mL); and the change from baseline in the CD4
+
T-cell count.
The safety analysis set included all randomly assigned pa-
tients who received at least 1 dose of study drug. All safety data
collected on or after the date the study drug was ﬁrst adminis-
tered and up to 30 days after the last dose of the study drug (if
patients discontinued treatment with the study drug) were
summarized descriptively by treatment group. Safety assess-
ments included adverse events, concomitant medication use,
laboratory tests (chemistry analysis, hematologic analysis, uri-
nalysis, and urine pregnancy analysis), 12-lead electrocardio-
grams, height, and weight. Adverse events were coded using the
Medical Dictionary for Regulatory Activities, version 14.0. The
estimated glomerular ﬁltration rate (eGFR) was calculated
using the Cockcroft-Gault method. The Fisher exact and Wil-
coxon rank sum tests were used to compare treatment-speciﬁc
differences in adverse event and continuous laboratory results,
respectively (SAS, version 9.2; SAS Institute, Cary, NC).
RESULTS
Screening of patients began in April 2010, and by November
2010, 698 patients had been randomly assigned to receive
COBI or RTV. Of these patients, 692 received one of the study
medications, with 344 receiving COBI and 348 receiving RTV
(Figure 1). Demographic and general baseline characteristics
Figure 1. Patient disposition through week 48 of the study. Abbreviations: COBI, cobicistat; RTV, ritonavir.
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were similar between the 2 treatment groups (Table 1). Overall,
39.7% of patients had a baseline HIV-1 RNA load of > 100 000
copies/mL. There was no difference in baseline eGFR between
the treatment groups. Rates of discontinuing treatment with
the study drug and reasons for discontinuation were similar
between treatment groups. The last patient’s week 48 visit was
completed in November 2011. At interim reviews and week 48,
the IDMC recommended that the study continue as planned.
The study met its primary objective of evaluating the nonin-
feriority of COBI versus RTV in combination with ATV and
FTC/TDF. In the COBI group, 293 of 344 patients (85.2%) had
an HIV-1 RNA load of < 50 copies/mL at week 48, compared
with 304 of 348 patients (87.4%) in the RTV group, by the FDA
snapshot ITT analysis (difference, −2.2% [95% CI, −7.4% to
3.0%]; Table 2). Other efﬁcacy end points also indicated that vi-
rologic responses to COBI and RTV were similar (Supplemen-
tary Table 1), including the FDA-deﬁned TLOVR analysis,
which showed comparable virologic suppression rates (82.8%
[285 of 344] in the COBI group and 85.3% [297 of 348] in the
RTV group; difference, −2.6% [95% CI, −8.1% to 2.8%]). The
proportion of patients with an HIV-1 RNA load of < 50 copies/
mL, determined by missing-equals-failure ITT analysis, was
also comparable between the 2 groups (Figure 2).
Responses toCOBIwere comparable to response to RTVacross
patient subgroups at week 48 (Supplementary Figure 1), includ-
ing patients with an HIV-1 RNA load of > 100 000 copies/mL
Table 1. Baseline Characteristics of Patients
Characteristic COBI (n = 344) RTV (n = 348)
Age, y 37 ± 9.8 38 ± 9.6
Women 57 (16.6) 61 (17.5)
Race
American Indian or
Alaska Native
1 (0.3) 2 (0.6)
Asian 44 (12.8) 37 (10.6)
Black or African heritage 65 (18.9) 63 (18.1)
Native Hawaiian or
Pacific Islander
1 (0.3) 1 (0.3)
White 198 (57.6) 215 (61.8)
Other 33 (9.6) 27 (7.8)
Unknown 2 (0.6) 3 (0.9)
Hispanic/Latino ethnicity 98 (28.5) 92 (26.4)
Body mass index, kg/m2a 25.2 ± 4.54 25.0 ± 4.70
HBsAg positivity 16 (4.7) 9 (2.6)
HCV antibody positivity 21 (6.1) 16 (4.6)
HIV-1 RNA load
Log10 copies/mL, median 4.78 4.84
>100 000 copies/mL 132 (38.4) 143 (41.1)
CD4+ T-cell count, cells/mm3 353 ± 170.5 351 ± 175.5
≤200 60 (17.4) 57 (16.4)
201 to ≤350 114 (33.1) 126 (36.2)
351 to ≤500 123 (35.8) 117 (33.6)
>500 47 (13.7) 48 (13.8)
Data are no. (%) of patients or mean value ± SD, unless otherwise indicated.
Abbreviations: COBI, cobicistat; HBsAg, hepatitis B virus surface antigen;
HCV, hepatitis C virus; RTV, ritonavir.
a Calculated as the weight in kilograms divided by the height in meters
squared.
Table 2. Virologic Outcome at Week 48 for the Intention-to-Treat
Set, Using Food and Drug Administration Snapshot Analysis
Virologic Outcome
COBI
(n = 344)
RTV
(n = 348)
Virologic success (HIV-1 RNA
load of <50 copies/mL)a
293 (85.2) 304 (87.4)
Difference: −2.2% (95%
CI: −7.4 to 3.0%)
(P= 0.40)
Virologic failure 20 (5.8) 14 (4.0)
HIV-1 RNA load ≥50 copies/mL 6 (1.7) 7 (2.0)
DC study drug because of lack of
efficacy
1 (0.3) 0
DC study drug for other reasonsb;
last available HIV-1 RNA load
≥50 copies/mL
13 (3.8) 7 (2.0)
No virologic data in week 48 window 31 (9.0) 30 (8.6)
DC study drug because of AEs
or death
22 (6.4) 23 (6.6)
DC study drug for other reasonsb;
last available HIV-1 RNA load
< 50 copies/mL
9 (2.6) 7 (2.0)
Missing data during window but
on study drug
0 0
Data are no. (%) of patients.
Abbreviations: AE, adverse event; COBI, cobicistat; DC, discontinued; HIV-1,
human immunodeficiency virus type 1; RTV, ritonavir.
a Defined as an HIV-1 RNA load of <50 copies/mL between days 309 and 378
(the week 48 window). The difference between the groups and its 95.2%
confidence interval were calculated on the basis of baseline HIV-1 RNA load
stratum–adjusted Mantel-Haenszel proportion analysis.
b Includes investigator’s discretion, withdrawal of consent, loss to follow-up,
treatment noncompliance, protocol violation, and pregnancy.
Figure 2. Patients achieving a human immunodeﬁciency virus type 1
(HIV-1) RNA load of < 50 copies/mL through week 48 of the study, accord-
ing to missing-equals-failure intention-to-treat analysis. Abbreviations:
COBI, cobicistat; RTV, ritonavir.
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at baseline (86.4% and 86.0%, respectively). Mean changes in
CD4+ T-cell counts at most time points were similar in the
COBI and RTV groups (+213 cells/mm3 and +219 cells/mm3,
respectively, at week 48).
Of the 692 randomly assigned and treated patients, 24
(3.5%) met criteria for resistance testing, with 12 of 344 (3.5%)
in the COBI group and 12 of 348 (3.4%) in the RTV group. Of
the 10 patients in the COBI group with available data, none de-
veloped resistance mutations to PIs or TDF; 2 developed resis-
tance mutations to FTC (M184V). Of the 12 patients in the
RTV group, none developed resistance mutations.
Reported adverse events are summarized in Table 3. Most
adverse events reported in each group were mild or moderate.
No patients died during the study. The numbers of patients
who discontinued treatment because of an adverse event were
identical in the 2 groups (25 [7.3%] in the COBI group and 25
[7.2%] in the RTV group; Table 4). The most common adverse
events, such as hyperbilirubinemia, jaundice, and scleral
icterus, were related to an elevated bilirubin level, which oc-
curred in a similar percentage of patients in the COBI and RTV
groups (40.7% and 36.2%, respectively); these were also the
most common adverse events leading to discontinuation of
treatment in both groups (3.5% in the COBI group and 3.2% in
the RTV group). The rates of diarrhea and nausea did not
differ between the 2 groups.
Renal adverse events leading to treatment discontinuation
were reported for 6 patients (1.7%) in the COBI group and 5
patients (1.4%) in the RTV group. In the COBI group, 1 of the
6 patients had baseline serum creatinine level of 0.86 mg/dL
and an eGFR of 70.0 mL/min and had treatment discontinued
in accordance with the study protocol because of a conﬁrmed
eGFR of < 50 mL/min, although the absolute change in serum
creatinine level was small (approximately +0.4 mg/dL); the pa-
tient’s serum creatinine level improved to 0.95 mg/dL after dis-
continuation of study treatment. The other 5 COBI recipients
had laboratory ﬁndings consistent with proximal tubulopathy,
such as hypophosphatemia, proteinuria, or normoglycemic gly-
cosuria; 4 of these 5 patients had follow-up data available. All 4
patients experienced improvement in their renal laboratory
values (serum creatinine, serum phosphate, urine protein, and
urine glucose levels) after discontinuing treatment with the
study drug. One patient had a complete reversal of the serum
creatinine level and all 3 other abnormal ﬁndings. The other 3
patients had complete reversal of hypophosphatemia, protein-
uria, or glycosuria, while the serum creatinine level improved.
One COBI recipient had no follow-up data after developing
proximal tubulopathy in the setting of Enterobacter sepsis and
acute renal failure (serum creatinine level, 5.07 mg/dL; eGFR,
17 mL/min). In the RTV group, 3 of the 5 patients had increas-
es in the serum creatinine level that were not accompanied by
features of proximal tubulopathy. In the other 2 patients who
had proximal tubulopathy, the serum creatinine level improved,
and other markers of proximal tubulopathy completely re-
versed; 1 patient started a regimen containing RTV. No patient
required dialysis. A small increase in the median serum creati-
nine level between baseline and week 48 was seen in the COBI
and RTV groups (+0.13 mg/dL and +0.09 mg/dL, respectively;
P < .001), and a corresponding decrease in the median eGFR
was also observed during this interval (−12.9 mL/min and
−9.1 mL/min, respectively; P < .001). Most of the change in
serum creatinine level in both groups occurred by week 8, with
little progression between weeks 8 and 48 (Figure 3).
Because of the safety proﬁle of TDF, bone safety was as-
sessed. Fractures occurred in 2 patients (0.6%) in the COBI
group and 4 patients (1.1%) in the RTV group; 1 patient in the
RTV group had nontraumatic spinal compression fracture,
which was considered old and not acute; all other fractures
were trauma related.
As expected with the use of boosted ATV, hyperbilirubine-
mia was the most common grade 3–4 laboratory abnormality
and was more common in the COBI group (65.3%, compared
with 56.6% in the RTV group). However, as mentioned above,
the rate of treatment discontinuation because of bilirubin-
related adverse events was low and similar in both groups. The
incidence of grade 3–4 elevation in liver enzyme levels was
Table 4. Adverse Events (AEs) Leading to Discontinuation of
Study Drug in >1 Patient in Either Group
AE COBI (n = 344) RTV (n = 348)
Scleral icterus 8 (2.3) 4 (1.1)
Jaundice 9 (2.6) 7 (2.0)
Hyperbilirubinemia 1 (0.3) 2 (0.6)
Rash 1 (0.3) 2 (0.6)
Allergic dermatitis 2 (0.6) 0
Data are no. (%) of patients.
Abbreviations: COBI, cobicistat; RTV, ritonavir.
Table 3. Common Adverse Events (AEs) Occurring in ≥10% of
Patients in Either Group
AE COBI (n = 344) RTV (n = 348) P
Jaundice 72 (20.9) 54 (15.5) .076
Scleral icterus 61 (17.7) 64 (18.4) .84
Nausea 61 (17.7) 57 (16.4) .69
Diarrhea 53 (15.4) 71 (20.4) .093
Headache 38 (11.0) 54 (15.5) .093
Nasopharyngitis 37 (10.8) 53 (15.2) .09
Hyperbilirubinemia 39 (11.3) 34 (9.8) .54
URTI 35 (10.2) 28 (8.0) .36
Data are no. (%) of patients.
Abbreviations: COBI, cobicistat; RTV, ritonavir; URTI, upper respiratory tract
infection.
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similar in the COBI and RTV groups (AST level, 2.9% and
2.0%, respectively; ALT level, 3.2% and 2.0%, respectively). One
subject from each group had grade 3–4 elevations in liver
enzyme levels (AST or ALT) and hyperbilirubinemia, along
with a direct bilirubin level of >1.5 mg/dL, which suggests that
the hyperbilirubinemia may not have been associated with
ATV. The subject in the COBI group had acute hepatitis C
virus infection, and the subject in the RTV group had suspected
acute hepatitis B virus infection.
Numerically smaller increases from baseline to week 48 in
the COBI group, compared with the RTV group, were observed
for fasting total cholesterol level (+5 mg/dL and +9 mg/dL, re-
spectively; P = .081) and triglycerides level (+19 mg/dL and
+32 mg/dL, respectively; P = .063). No other differences were
observed between treatment groups in safety-associated labora-
tory ﬁndings, body weight, or electrocardiogram results.
DISCUSSION
In this large, randomized, double-blinded study, COBI demon-
strated high efﬁcacy that was comparable and noninferior to
that of standard-of-care RTV as a pharmacoenhancer of ATV.
The results were consistent across a range of end points,
including the primary FDA-deﬁned snapshot analysis, the
TLOVR algorithm, and a per-protocol (as-treated) analysis. In
addition, the response in the COBI group was comparable to
that in the RTV group across all subgroups; virologic success
rates in patients with a baseline HIV-1 RNA load of >100 000
copies/mL were high and comparable in the 2 treatment
groups. Virologic suppression in this study (85% in the COBI
group vs 87% in RTV group) was similar to that seen in other
recent randomized clinical trials of boosted PIs plus FTC/TDF
at week 48 that reported conﬁrmed virologic response: in the
ARTEMIS study, the rate of virologic suppression was 84% in
the darunavir (DRV) + RTV group and 78% in the lopinavir
(LPV)/RTV group, according to per-protocol analysis [10]; in
the CASTLE study, the rate of virologic suppression was 78% in
the ATV + RTV group and 76% in the LPV/RTV 76%, accord-
ing to ITT analysis [11].
In phase 2 trials, COBI rapidly induced a small increase in
the serum creatinine level, with a consequent reduction in the
eGFR [3, 12, 13]. This phenomenon is due to COBI’s inhibition
of the tubular secretion of creatinine, with no effect on the
actual GFR, as measured by iohexol clearance [13]. RTV has
also been shown to inhibit MATE-1, a renal transporter used
for tubular secretion of creatinine [14]. Consistent with these
ﬁndings, a small increase in serum creatinine was seen in both
the COBI and RTV group in our study. The changes in serum
creatinine level in both groups were observed as early as week 2
and appeared to stabilize by week 8, without further increase
through week 48. Some observational studies found that
boosted PI regimens used with TDF may be associated with a
higher incidence of chronic kidney disease or a greater decrease
in the eGFR [15, 16]. However, given the inhibitory effect of
RTV on creatinine tubular secretion, studies that use serum cre-
atinine or its derivatives, such as the eGFR, as the primary renal
outcome need to be interpreted with caution.
Rates of renal function–associated treatment discontinuation
in our study (1.7% in the COBI group vs 1.4% in the RTV
group) were consistent with those reported in previous studies.
In ACTG5202, 6 of 464 patients (1.3%) receiving ATV boosted
by RTV plus FTC/TDF discontinued treatment with or
reduced the dose of FTC/TDF because of changes in renal func-
tion [17]. Other studies of TDF-containing boosted PI regimens
found similar rates, ranging from 0% to 3%, of renal function–
associated discontinuation of (or switch from) TDF therapy
[18–26]. In our study, a small and similar number of patients
discontinued study drug because of proximal tubulopathy (5
COBI recipients and 2 RTV recipients). This is consistent with
the safety proﬁle of TDF, which has been associated with proxi-
mal tubulopathy (or Fanconi syndrome) [27]. In all patients
who developed proximal tubulopathy and had follow-up data,
tubular abnormalities (proteinuria, glycosuria, or hypophos-
phatemia) reversed, and the serum creatinine level improved.
The current study will continue in a blinded fashion to further
Figure 3. Change in serum creatinine level (A) and estimated glomeru-
lar ﬁltration rate (eGFR; B) through week 48 of the study. Whiskers denote
interquartile ranges (IQRs).
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assess the long-term safety of COBI, including renal safety,
using investigator-reported adverse events and renal laboratory
parameters (serum creatinine, serum phosphate, urine protein,
and urine glucose levels).
The gastrointestinal tolerability of COBI was similar to that of
RTV. Gastrointestinal adverse events, such as nausea, vomiting
(7.3% vs 4.6%), or diarrhea, were similar between the 2 groups,
were mostly of mild severity, and rarely led to discontinuation of
study drug treatment (1 COBI recipient discontinued treatment
because of vomiting, 1 RTV recipient discontinued because of
nausea, and none discontinued because of diarrhea).
Our study does not provide data for HIV-infected patients
with lower eGFRs, because an eGFR of at least 70 mL/min was
required at study entry. A study to evaluate the use of COBI as
a pharmacoenhancer for PI (ATV or DRV) or as a component
of the single-tablet regimen EVG/COBI/FTC/TDF in patients
with an eGFR of 50–90 mL/min (clinical trials registration
NCT01363011) is ongoing.
Notably, the mean baseline CD4+ T-cell count for patients in
both treatment arms exceeded 350 cells/mm3. This high base-
line CD4+ T-cell count reﬂects a trend toward initiation of HIV
therapy at earlier stages of disease and is in line with recent
HIV treatment guidelines, which recommend antiretroviral
therapy for all individuals with HIV infection, regardless of
CD4+ T-cell count [4, 5].
The lack of antiretroviral activity of COBI is an advantage
over RTV, which may lead to PI resistance if used as a pharma-
coenhancer of a non-PI (eg, EVG) [2]. In addition, the physio-
chemical properties of COBI, such as high intrinsic solubility
and dissolution rate, make it amenable to coformulation with
≥1 antiretroviral agent [28]. Currently, COBI is being devel-
oped not only as a stand-alone pharmacoenhancer, but also as
a component of several ﬁxed-dose combination tablets that
contain EVG, ATV, or DRV.
In conclusion, COBI demonstrated high and noninferior efﬁ-
cacy as a pharmacoenhancer of ATV, compared with standard-
of-care RTV. The renal safety proﬁle of COBI is similar to that
of other TDF-containing, RTV-boosted PI regimens. COBI
may become an important alternative to RTV as a pharma-
coenhancer.
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